APGE — Apogee Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Apogee Therapeutics Announces Positive Interim Results From Phase 1B Trial Of Apg808
U.S. STOCKS ON THE MOVE-MeiraGTx, CervoMed, Natgas companies
U.S. STOCKS ON THE MOVE-Metropolitan Bank, Fossil, MeiraGTx
Citi initiates Apogee with "buy" rating on potential for eczema drug
U.S. STOCKS ON THE MOVE-Novo Nordisk, Intel, Microsoft
Citi starts coverage on 'insulated' SMid biotechs amid healthcare policy uncertainty
Brief: Apogee Therapeutics Inc - Enters Master Services Agreement With Samsung Biologics
Brief: Apogee Therapeutics Announces Positive Interim Phase 1 Results From The APG990 Healthy Volunteer Trial
U.S. RESEARCH ROUNDUP-Allstate, Mongodb, Primerica
Brief: Apogee Therapeutics Announces First Participants Dosed In Phase 1 Clinical Trial Of Apg990
Brief: Apogee Therapeutics Inc Files For Mixed Shelf - SEC Filing
Brief: Apogee Therapeutics Expands Board Of Directors With The Appointment Of Lisa Bollinger, MD
Brief: Apogee Announces First Participants Dosed in Phase 1 Trial of APG808 for Chronic Obstructive Pulmonary Disease (COPD)
Brief: Apogee Therapeutics Announces Closing Of Upsized Public Offering
Brief: Apogee Therapeutics Inc Announces Underwritten Public Offering Of 6.8 Million Shares Of Common Stock At A Public Offering Price Per Share Of $62.
U.S. RESEARCH ROUNDUP-Arrivent Biopharma, Ferguson, Target
Brief: Apogee Therapeutics Announces Proposed Underwritten Public Offering
U.S. STOCKS ON THE MOVE-Nasdaq, Albemarle, Haemonetics
U.S. STOCKS ON THE MOVE-AeroVironment, Tesla, GitLab